
Xenitra (ASX: XEN) has transformed from a tourism-dependent retailer into a diversified cross-border platform connecting Australian and New Zealand health and consumer brands with Greater China. Revenue has grown roughly 15-fold from A$2.7m in FY23 to A$39.8m in FY25, while the company remains valued at only ~0.3x FY25 sales. With growth across nutritionals, OTC medicines and its OPAL platform, supported by major partnerships and favourable Chinese market tailwinds, Xenitra appears positioned for significant margin and earnings growth. A DCF valuation of A$0.0096–A$0.0137 per share implies substantial upside from the current A$0.003 share price.
.webp&w=828&q=75)
Benz Mining Corp (ASX: BNZ) advances its Glenburgh Gold Project toward resource definition, delivering high‑grade intercepts, strong funding, and district‑scale potential that positions it as one of Australia’s most aggressive gold growth stories.
.webp&w=828&q=75)
Myer Holdings (ASX: MYR) delivers strong 1H26 sales growth, disciplined cost control, and record cash generation, reinforcing operational momentum and strategic execution across its integrated retail and apparel platform.
.webp&w=828&q=75)
Sunrise Energy Metals (ASX: SRL) advances its Syerston Scandium Project toward FID, expands production scope, and deepens downstream exposure through U.S. semiconductor investment, positioning for structural re‑rating amid tightening scandium supply.

Power Minerals is drawing attention after strong Morro do Ferro rare-earth drilling, rising trading activity and a breakout above long-held resistance, while further assays and a maiden resource estimate remain key upcoming catalysts.
.webp&w=828&q=75)
American Tungsten & Antimony (ASX: AT4) advances its US antimony and tungsten strategy through refinery plans, exploration results and a technical breakout setup, highlighting new project developments and potential growth opportunities.